Erich Horsley News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Erich horsley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Erich Horsley Today - Breaking & Trending Today
Biosplice Publishes Phase 2B Lorecivivint Analysis Showing globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis Biosplice’s Phase 2b trial for lorecivivint hits primary endpoint in osteoarthritis pain SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of its successful Phase 2b knee osteoarthritis clinical trial data in Osteoarthritis and Cartilage. In this 24-week clinical trial, Biosplice’s groundbreaking knee OA drug candidate, lorecivivint, met primary endpoints of Pain NRS (daily pain measurement) at both 12 and 24-week timepoints. As in previous trials, lorecivivint appeared safe and well tolerated. “Healthcare professionals need an approach for treating knee osteoarthritis that can provide durable pain relief, improve functionality, and be safely utilized over a long period of time,” said Biosplice ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to . Biosplice Therapeutics, Inc.April 22, 2021 GMT SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, and Samil Pharmaceutical Co. Ltd. (“Samil”), a pharmaceutical company based in the Republic of Korea, announced the execution of a licensing agreement which grants Samil the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis (“OA”) in the Republic of Korea. ....